time is the key
in cancer diagnosis
This is why we have created InProbe – minimally invasive medical device
capable of real-time diagnostics of HER2 breast cancer and HER2 stomach
cancer biomarkers.
learn More

About inProbe

Global potential to replace current ihc and fish cancer diagnostics with possible far less-invasive substitution to the biopsy cancer diagnostics

INPROBE, invented and developed by SDS Optic, is cancer diagnosis device designed to reduce time of medical diagnosis, increase precision and effects of advanced cancer treatments and most importantly – help medical professionals to save lives

of milions of patients worldwide. It can be used both in cancer diagnostics and ther- apies monitoring in real-time and natural state (in vivo), thus giving the medical pro- fessionals tools and methods previously unavailable.

Key benefits

Real time diagnostic
Cancer biomarkers testing results (currently HER2) are presented live on the screen
Objective results
Results are objective, numerical and easy to read.
Patients wellbeing
No need for the tissue acquisition from the patient’s body and micro-size of the needle are significantly less painful than biopsy.

How it works

InProbe is a nano-size glass probe getting in vivo within very thin biopsy needle, connected with detecting device and with innovative components at the tip of the probe. Thanks to its thicknes it is safer, much less stressful and much less painful.
Fast and precise cancer diagnosis combined with modern therapies can help to SAVE UP TO 30% of people diagnosed with cancer by year 2030.
Thanks to high sensitivity inProbe can examine even single cells. It also allows to get close to the tumor without the need to get into the tumor as today, which can lead to malignant cancer.

All the data gathered during procedure is transferred via fiber optics into the multi- purpose detecting device. Then the data is calculated using specific algorithms and presented to the oncologist as a diagnostic result – a numerical measure with exact level of tested components (e.g. HER2 cancer biomarker).
During the cancer therapies inProbe will be able to measure active ingredient level (f.e. Trastuzumab) in cancer tumor cells, thus supporting & improving the efficiency of modern targeted cancer therapies and petients’ well-being.


SDS-MicroProbe can be a groundbreaking solution to overcome problems
in current technology and enable analysis of biological processes inside the single cell in their natural state. As an expert in hematology, I am
convinced that such solution would find several applications in research as well as
in future cell therapies in the cancer area.

Hematologist/Oncologist M.D. PhD
with several years of scientific experience at NIH
Bethesda, MD, USA

There is an unmet need to study biological processes within individual cells residing in their native niche. The SDS-MicroProbe addresses this shortcoming; it is a new approach in analyzing key intracellular parameters that indicate the functionality of a cell. The SDS-MicroProbe has the potential to substantially advance our ability to assess the status of living cells and thereby improve our ability to diagnose various diseases and evaluate the efficiency of interventions.

Profesor, PhD of Harvard Medical School
Boston, MA, USA

About SDS Optic


At SDSOPTIC we strive to make difference in the world. We are connecting vast medical knowledge with technical skills to create medical devices that can revolutionise healthcare in the world.

Our team consists of renown experts in biology, medicine, advanced technologies, chemistry and related sciences. Our strategy is to discover, develop, produce and commercialise on global scale unique diagnostics and monitoring tools working in real-time and in natural state, which support and save Lifes.

We concentrate on helping the healthcare with faster, less painful diagnostics and supporting targeted, effective treatment procedures. We develop and create different diagnostics & monitoring solutions, including the ones used in cancer diagnostics and cancer treatment.

time line of sds optic

Core team

Magdalena Staniszewska, Ph.D.
Co-Founder / Chief Science Officer
Leading biotechnology scientis with several years of experience at Harvard Medical School in Boston, MA (USA) and Polish Academy of Sciences. A scientist with broad experience in discovering molecular bases of diseases, identifying targets and developing novel therapeutic strategies for diabetic complications, cancer and eye diseases. Co-invented analytical tools and diagnostic markers of pathological neovessels, holds track record of scientific publications and public speaking.
Marcin Staniszewski, Msc.
Co-Founder, CEO & Senior Engineer
Experienced scientist and engineer with several years of experience in R&D engineering projects obtained at US companies, incl. NASA Laboratory and Glenn Research Center in Cleveland, OH. University of Akron (Akron, OH) graduate, founder of several technology startups in United States.
Mateusz Sagan, MBA
Chief Business Officer / Member of the Supervisory Board
Experienced leader and manager specialised in strategic management, sales management and development of biotechnology startups. Graduate of the University of Central Lancashire in Preston, UK. Dozens years as CEO and Board Executive for large international corporate business with strong ledership and vision building expertise.
Przemysław Kopyto, M.D.
Chief Medical Officer
Lublin Medical University M.D. & Harvard Business School graduate. Oncology pharma market expert, dozens years spent with big pharma as Head of Immunology and Oncology business units. Run several clinical trials and marketed several oncology medicines.
Development and commercialization of inProbe by SDS Optic supported by:

partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic partner SDS Optic

Website design co-financed under the European Regional Developent Fund